Delaware Supreme Court Affirms D&O Coverage in Merger Settlement Despite ‘Bump-Up’ Exclusion

Why It Matters

The ruling tightens insurers’ ability to deny D&O coverage in merger disputes, protecting corporate officers from unexpected out‑of‑pocket exposure and setting a clear precedent for future bump‑up exclusion arguments.

Key Takeaways

• Delaware Supreme Court upheld D&O coverage for $28M settlement.
• Insurers must prove settlement is effective increase in deal price.
• Court found settlement reflected litigation costs, not price bump.
• Bump‑up exclusion requires two‑step analysis; second step failed.
• Ruling clarifies insurers' burden in merger‑related D&O claims.

Pulse Analysis

The decision arrives at a pivotal moment for directors‑and‑officers liability insurance, a market that has grown alongside increasingly complex M&A activity. Bump‑up exclusions, designed to prevent insurers from subsidising an undervalued acquisition, are commonplace in D&O policies. However, the Delaware Supreme Court’s two‑step framework—first confirming the claim’s nature, then demanding proof that the settlement truly raises the purchase price—adds a nuanced layer of scrutiny. By dissecting the Harman settlement’s composition, the court highlighted that payments tied to legal defence costs do not satisfy the “effective increase” requirement.

Legal practitioners and risk managers must now reassess how they structure settlement negotiations in merger‑related disputes. Insurers will need to produce detailed valuation analyses, expert testimony, or clear contractual links demonstrating that a payout directly augments the consideration paid to shareholders. Absent such evidence, courts are likely to side with policyholders, as seen in Harman’s case where the class included shareholders who never received merger proceeds. This heightened evidentiary threshold may encourage more precise policy language and proactive claim‑management strategies to avoid costly litigation.

For the broader market, the ruling signals stronger protection for corporate officers facing shareholder litigation over disclosure or valuation issues. It may also influence underwriting standards, prompting insurers to refine exclusion clauses or adjust premiums for high‑risk M&A transactions. Companies can leverage this precedent to negotiate more favorable D&O terms, ensuring that legitimate settlement costs remain indemnified. Ultimately, the decision underscores the importance of aligning insurance coverage with the actual financial impact of disputes, rather than allowing blanket exclusions to erode corporate risk‑transfer mechanisms.